Patents by Inventor George T. Topalov

George T. Topalov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 9809590
    Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 7, 2017
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20170240547
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Application
    Filed: May 10, 2017
    Publication date: August 24, 2017
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang, Charles R. Heap, Mark Hadden, Wenge Cui, Hélène Decornez, Shuang Liu
  • Imidazo(4,5-) pyridin-2-yl amides as K7 channel activators
    Patent number: 9650376
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 16, 2017
    Assignee: KNOPP BIOSCIENCES LLC
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang, Charles R. Heap, Mark Hadden, Wenge Cui, Hélène Decornez, Shuang Liu
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20170114022
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 27, 2017
    Inventors: Scott S. Harried, Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, David A. Mareska, Kai Zhang
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 9481653
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 1, 2016
    Assignee: KNOPP BIOSCIENCES LLC
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20160075663
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 17, 2016
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang
  • IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20160031875
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Inventors: Lynn Resnick, George T. Topalov, Steven A. Boyd, Justin K. Belardi, Charles A. Flentge, James S. Hale, Scott S. Harried, David A. Mareska, Kai Zhang, Charles R. Heap, Mark Hadden, Wenge Cui, Hélène Decornez, Shuang Liu
  • SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20160002232
    Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 9174981
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: November 3, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Triazolopyridine compounds as PIM kinase inhibitors
    Patent number: 8987251
    Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 24, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Hicks, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
    Patent number: 8865726
    Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: October 21, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Lisa A. De Meese, Jay Bradford Fell, John P. Fischer, John A. Josey, Kevin Koch, Yvan Le Huerou, Gregory F. Miknis, Martha E. Rodriguez, George T. Topalov, Eli M. Wallace, Rui Xu
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
    Patent number: 8841455
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: September 23, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Michael F. Bradley, Robert Kirk DeLisle, D. David Hennings, April L. Kennedy, Fredrik P. Marmsater, Matthew David Medina, Mark C. Munson, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
    Publication number: 20140045817
    Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Hicks, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • Triazolopyridine compounds as PIM kinase inhibitors
    Patent number: 8575145
    Abstract: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: November 5, 2013
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Greschuk, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20130274244
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 17, 2013
    Inventors: Mark Laurence Boys, Robert Kirk Delisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsater, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors
    Publication number: 20120258952
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 11, 2012
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Laurence Boys, Michael F. Bradley, Robert Kirk DeLisle, D. David Hennings, April L. Kennedy, Fredrik P. Marmsater, Matthew David Medina, Mark C. Munson, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
    Publication number: 20120178715
    Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.
    Type: Application
    Filed: September 3, 2010
    Publication date: July 12, 2012
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Lisa A. De Meese, Jay Bradford Fell, John P. Fischer, John A. Josey, Kevin Koch, Yvan Le Huerou, Gregory F. Miknis, Martha E. Rodriguez, George T. Topalov, Eli M. Wallace, Rui Xu
  • Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
    Patent number: 8138181
    Abstract: Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: March 20, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Julie Marie Greschuk, Nicholas C. Kallan, Fredrik P. Marmsäter, Mark C. Munson, James P. Rizzi, John E. Robinson, Stephen T. Schlachter, George T. Topalov, Qian Zhao, Joseph P. Lyssikatos
  • TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
    Publication number: 20110144085
    Abstract: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
    Type: Application
    Filed: August 18, 2009
    Publication date: June 16, 2011
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Shelley Allen, Laura L. Celeste, T. Gregg Davis, Robert Kirk DeLisle, Julie Marie Greschuk, Stefan D. Gross, Erik James Hicken, Leila J. Jackson, Nicholas C. Kallan, Joseph P. Lyssikatos, Fredrik P. Marmsater, Mark C. Munson, Jed Pheneger, Bryson Rast, John E. Robinson, Stephen T. Schlachter, George T. Topalov, A. Dale Wright, Qian Zhao
  • IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20100144751
    Abstract: Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
    Type: Application
    Filed: March 27, 2008
    Publication date: June 10, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Fredrik P. Marmsater, Mark C. Munson, James P. Rizzi, John E. Robinson, Stephen T. Schlacter, George T. Topalov, Joseph P. Lyssikatos